Committee

Orphan designation: (6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid Treatment of systemic sclerosis, 12/01/2017 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Finger, Growth, Face, Blood, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Systemic scleroderma, EMA, IRIS, Protein, Scleroderma, CB2, European, Collagen, COMP, Connective tissue, Skin, Heart, Sponsor, European Commission, Immune system, The, Safety, Swelling, Marketing, Pharmaceutical industry

Orphan designation: (6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid Treatment of systemic sclerosis, 12/01/2017 Withdrawn

Key Points: 


Orphan designation: (6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid Treatment of systemic sclerosis, 12/01/2017 Withdrawn

Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Ovarian cancer, GM, Gene, Survival, Disease, Patient, Committee, Knowledge, GM-CSF, Cancer, Female, Regulation, EMA, IRIS, Woman, European, Therapy, COMP, Sponsor, European Commission, Immune system, Safety, Marketing, Medicine, Pharmaceutical industry

Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn

Key Points: 


Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Brain, Ornithine decarboxylase, Enzyme, Growth, Weakness, Survival, Cell, Neuroblastoma, Disease, Patient, Tablet, Committee, Knowledge, Abdomen, Regulation, Child, Cancer, EMA, IRIS, Bone pain, Mouth, European, Polyamine, Fever, COMP, Sponsor, European Commission, Spine, Safety, Marketing, Limited, Medicine, Pharmaceutical industry

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Key Points: 


Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Ovarian cancer, Enzyme, DNA repair, Abbott Laboratories, Survival, Disease, Patient, Committee, Knowledge, DNA, Cancer, Female, Regulation, Laboratory, EMA, IRIS, Ludwigshafen, Woman, PARP, European, COMP, Sponsor, European Commission, Fibroadenoma, Safety, Marketing, Medicine, Pharmaceutical industry

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Key Points: 


Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Brain, Disease, Coagulation, Patient, Committee, Knowledge, Internal, Regulation, Haemophilia, EMA, IRIS, Joint, Human, Wound healing, European, COMP, Bleeding, Spinal cord, Antibody, Sponsor, European Commission, Immune system, Safety, Factor IX, Blood, Marketing, Haemophilia B, Medicine, Pharmaceutical industry

Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

Key Points: 


Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

FEMSA Shareholders’ Meeting Resolutions

Retrieved on: 
Monday, March 25, 2024
FMX, Annual, Annual report, BMV, Committee, ADS, Audit committee, Shareholder, Bank statement, Woman, Operation, Series

de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) held its Annual Shareholders’ Meeting today (“the Shareholders’ Meeting”), during which the shareholders approved the consolidated financial statements for the year ended December 31, 2023, the 2023 CEO’s annual report and the opinion of the Board of Directors for the year 2023.

Key Points: 
  • de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) held its Annual Shareholders’ Meeting today (“the Shareholders’ Meeting”), during which the shareholders approved the consolidated financial statements for the year ended December 31, 2023, the 2023 CEO’s annual report and the opinion of the Board of Directors for the year 2023.
  • In line with our goal of setting the standard for corporate governance best practices, the shareholders’ meeting elected Elane Stock and Olga Gonzalez Aponte as new independent directors.
  • Additionally, the Annual Shareholders’ Meeting declared and approved the payment of an extraordinary cash dividend of Ps.
  • For additional information, please refer to the Summary of Resolutions in the Shareholders Meeting section of our corporate website at: https://femsa.gcs-web.com/shareholder-meeting-information

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
Thursday, March 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Northland Power Announces President and Chief Executive Officer Leadership Transition

Retrieved on: 
Monday, March 25, 2024
Growth, Wind, NPI, TSX, Committee, Lead, Management

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced that Mike Crawley, Northland’s President and Chief Executive Officer, and the Board of Directors have agreed to a change in leadership for the Company.

Key Points: 
  • TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced that Mike Crawley, Northland’s President and Chief Executive Officer, and the Board of Directors have agreed to a change in leadership for the Company.
  • As such, Mr. Crawley, after leading Northland for the past six years, will be stepping down from his role.
  • Under the succession plan, Mr. Crawley will remain with Northland until September 30, 2024.
  • John Brace, Chair of the Board of Directors, has been appointed Executive Chair as of today and will act as a bridge between Mr. Crawley and the next President & CEO as part of the transition.

Turtle Creek Asset Management Releases Open Letter to Gildan Board Calling on it to Hold the Annual Meeting Without Delay

Retrieved on: 
Monday, March 25, 2024
Face, EVP, Committee, Name, Proxy, Chairperson, Contemporary art, Sale, News, LLP

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) --  Turtle Creek Asset Management Inc. (“Turtle Creek”), a Canadian independent investment management firm with a 25-year history and a decade-long shareholder of Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or the “Company”), today issued an open letter to the board of directors (the “Board”) of Gildan.

Key Points: 
  • This Board does not have a mandate, nor the confidence of Gildan shareholders, to run a process that could result in the sale of Gildan.
  • The Board’s outrageous and unprecedented actions to date, in the face of massive shareholder opposition are wholly-disqualifying.
  • Turtle Creek believes that the process led by the Special Committee is yet another attempt by the Board to evade accountability for its actions.
  • For over 25 years, Turtle Creek has done the hard work of analyzing and valuing the companies in which we invest.

Michael Fernández of V-me Media Inc. Appointed As Member of The FCC Communications Equity and Diversity Council (CEDC)

Retrieved on: 
Monday, March 25, 2024
FCC, Employment, Disability, Communication, Religion, Committee, Digital newspaper, Small business, Marketing, Commission, Woman, Federal, CEDC, Federal Communications Commission

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- V-me Media Inc. is pleased to announce that Michael Fernández, our VP of Marketing & People has been named to the Federal Communications Commission (FCC) Communications Equity and Diversity Council.

Key Points: 
  • MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- V-me Media Inc. is pleased to announce that Michael Fernández, our VP of Marketing & People has been named to the Federal Communications Commission (FCC) Communications Equity and Diversity Council.
  • “I am honored to have been selected by the FCC to support this very important diversity initiative,” Michael Fernández said.
  • “This appointment provides a significant platform to advocate for and enhance the visibility and influence of Hispanic-owned and operated media companies, like V-me Media.
  • The CEDC will hold its first meeting on Wednesday, March 27, 2024.